Case Report

Fetal and Neonatal Graves Disease: A Case Report and Review of the Literature

Authors: Muhammad Aslam, MD, Musaddaq Inayat, MD

Abstract

Fetal and neonatal thyrotoxicosis from maternal Graves disease is a very rare entity. Fetal symptoms result from the transplacental passage of thyroid-stimulating immunoglobulins, which persist in the neonate resulting in neonatal symptoms. We present a case of fetal and neonatal thyrotoxicosis from maternal Graves disease. Fetal symptoms were controlled with maternal administration of antithyroid drugs leading to fetal thyroid inhibition. We present this case with a brief review of the literature.


Key Points


* Maternal Graves disease can lead to fetal and neonatal thyrotoxicosis.


* Fetal management requires maternal administration of antithyroid drugs for passive transfer to the fetus.


* Neonatal treatment is achieved with antithyroid drugs with the goal of a euthyroid state to prevent hyper- or hypothyroidism.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1.Burrow GN. The management of thyrotoxicosis in pregnancy. N Engl J Med 1985;313:562–565.
 
2.Karabulut N, Martin DR, Yang M, et al. MR imaging findings in fetal goiter caused by maternal graves disease. J Comput Assist Tomogr 2002;26:538–540.
 
3.Mestman JH. Hyperthyroidism in pregnancy. Clin Obstet Gynecol 1997;40:45–64.
 
4.Matsuura N, Konisi J, Fujieda K, et al. TSH-receptor antibodies in mothers with Graves’ disease and outcome in their offspring. Lancet 1988;1:14–17.
 
5.Skuza KA, Sills IN, Stene M, et al. Prediction of neonatal hyperthyroidism in infants born to mothers with Graves disease. J Pediatr 1996;128:264–268.
 
6.Fisher DA. Fetal thyroid function: diagnosis and management of fetal thyroid disorders. Clin Obstet Gynecol 1997;40:16–31.
 
7.Chan GW, Mandel SJ. Therapy insight: management of Graves’ disease during pregnancy. Nat Clin Pract Endocrinol Metab 2007;3:470–478.
 
8.Luton D, Le Gac I, Vuillard E, et al. Management of Graves’ disease during pregnancy: the key role of fetal thyroid gland monitoring. J Clin Endocrinol Metab 2005;90:6093–6098.
 
9.Volumenie JL, Polak M, Guibourdenche J, et al. Management of fetal thyroid goitres: a report of 11 cases in a single perinatal unit. Prenat Diagn 2000;20:799–806.
 
10.Davidson KM, Richards DS, Schatz DA, et al. In utero treatment of fetal goiter and hypothyroidism. N Engl J Med 1991;324:543–546.
 
11.Chattaway JM, Klepser TB. Propylthiouracil versus methimazole in treatment of Graves’ disease during pregnancy. Ann Pharmacother 2007;41:1018–1022.
 
12.Di Gianantonio E, Schaefer C, Mastroiacovo PP, et al. Adverse effects of prenatal methimazole exposure. Teratology 2001;64:262–266.
 
13.Redmond GP. Propranolol and fetal growth retardation. Semin Perinatol 1982;6:142–147.